Breaking News, Financial News

Financial Report: Biogen Idec

Revenues up 32% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec   3Q Revenues: $1.8 billion (+32%) 3Q Earnings: $488 million (+22%) YTD Revenues: $5.0 billion (+21%) YTD Earnings: $1.4 billion (+29%) Comments: Growth was driven by Tysabri and new MS therapy Tecfidera, with revenues totaling $286 million in the quarter. Avonex sales were flat at $733 million. Tysabri revenues increased 46% to $401 million as a result of gaining full rights from Elan in 2Q13. Rituxan revenues from an unconsolidated joint business arrangement were $303 million i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters